Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform

Cell Reports Medicine(2025)10.1016/j.xcrm.2025.102198Source: DataRank Database

Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform is a research paper published in Cell Reports Medicine (2025). On theSindex it has a DataRank of 0.241. It has been cited 4 times.

N/A

0.241DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

Linked data & code

gen nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 1.83)OA: goldTopics (52)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.241

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (22)

Zehua Li ORCID,Jessica Ritter ORCID,Elliott J. Brea ORCID,Navin R. Mahadevan ORCID,Deborah Dillon ORCID

Live enrichment

PubMed:40543510 PMC:PMC12281382 OpenAlex:https://openalex.org/W4411489430

National Cancer Institute

Grant: R01 CA258688

Dana-Farber Cancer Institute

Grant: 93085

NCI NIH HHS

Grant: K08 CA270077

National Cancer Institute

Dana-Farber Cancer Institute

Foundation for the National Institutes of Health

FWCI

1.83

Citation Percentile

0.9%

Citation Trend

2025

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.xcrm.2025.102198

publisherhttps://doi.org/10.1016/j.xcrm.2025.102198

publisherhttps://api.elsevier.com/content/article/PII:S266637912500271X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S266637912500271X?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40543510

Fields of Study

CAR-T cell therapy researchVirus-based gene therapy researchinterferon and immune responsesTriple Negative Breast NeoplasmsAnimalsMembrane ProteinsHumansFemaleMiceTumor MicroenvironmentImmunotherapy, AdoptiveCell Line, TumorPolyethylene GlycolsT-LymphocytesReceptors, Chimeric AntigenSTING Protein

MeSH Terms

Receptors, Chimeric AntigenSTING ProteinAnimalsFemaleHumansMembrane ProteinsPolyethylene GlycolsT-LymphocytesImmunotherapy, AdoptiveCell Line, TumorMiceTumor MicroenvironmentTriple Negative Breast Neoplasms

Keywords

StingStimulator of interferon genesMedicineBreast cancerTumor microenvironmentTriple-negative breast cancerContext (archaeology)Cancer immunotherapyImmunotherapyT cellAgonistCancerImmunologyCancer researchImmune systemPharmacologyInternal medicineReceptorBiologyInnate immune systemCar T CellsSting AgonistPeg Marker

Sustainable Development Goals

SDG 0: Good health and well-being